[1] Jennette J C, Falk R J, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference[J]. Arthritis Rheum, 1994, 37(2): 187-192.
[2] Mouthon L, Le Toumelin P, Andre M H, et al. Polyarteritis nodosa and Churg-Strauss angiitis: characteristics and outcome in 38 patients over 65 years[J]. Medicine: Baltimore, 2002, 81(1): 27-40.
[3] Yoo B W, Song J J, Park Y B, et al. Clinical features of Korean elderly patients with antineutrophil cytoplasmic antibody-associated vasculitis[J]. Korean J Intern Med, 2021, 36(3): 731-741.
[4] Tsurikisawa N, Oshikata C, Kinoshita A, et al. Longterm prognosis of 121 patients with eosinophilic granulomatosis with polyangiitis in Japan[J]. J Rheumatol, 2017, 44(8): 1206-1215.
[5] Masi A T, Hunder G G, Lie J T, et al. The American College of Rheumatology 1990 Criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)[J]. Arthritis Rheum, 1990, 33(8): 1094-1100.
[6] Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management[J]. Eur J Intern Med, 2015, 26(7): 545-553.
[7] Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa[J]. Am J Pathol, 1951, 27(2): 277-301.
[8] Jennette J C, Falk R J, Bacon P A, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides[J]. Arthritis Rheum, 2013, 65(1): 1-11.
[9] Greco A, Rizzo M I, De Virgilio A, et al. Churg-Strauss syndrome[J]. Autoimmun Rev, 2015, 14(4): 341-348.
[10] Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate[J]. Arthritis Rheum, 2004, 51(1): 92-99.
[11] Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials[J]. J Autoimmun, 2013, 43: 60-69.
[12] 张婷, 王芊霖, 彭敏, 等. 老年嗜酸性肉芽肿性多血管炎患者临床特点及预后[J]. 中华老年多器官疾病杂志, 2021, 20(4): 278-284.
[13] Uchiyama M, Mitsuhashi Y, Yamazaki M, et al. Elderly cases of Churg-Strauss syndrome: case report and review of Japanese cases[J]. J Dermatol, 2012, 39(1): 76-79.
[14] Suppiah R, Robson J C, Grayson P C, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis[J]. Ann Rheum Dis, 2022, 81(3): 321-326.
[15] Thomson C C, Tager A M, Weller P F. Clinical problem-solving. more than your average wheeze[J]. N Engl J Med, 2002, 346(6): 438-442.
[16] Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term follow up of the 383 patients enrolled in the French vasculitis study group cohort[J]. Arthritis Rheum, 2013, 65(1): 270-281.
[17] Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up[J]. Allergy, 2009, 64(4): 589-595.
[18] Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)[J]. Eur Respir J, 2016, 48(5): 1429-1441.
[19] Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group (FVSG) cohort[J]. Medicine: Baltimore, 2011, 90(1): 19-27.
[20] 嗜酸性肉芽肿性多血管炎诊治规范多学科专家共识编写组. 嗜酸性肉芽肿性多血管炎诊治规范多学科专家共识[J]. 中华结核和呼吸杂志, 2018, 41(7): 514-521.
[21] Mavrogeni S, Karabela G, Gialafos E, et al. Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance[J]. Inflamm Allergy Drug Targets, 2013, 12(5): 322-327.
[22] Sridharan S, Nanthakumaran S, Somagutta M R, et al. The critical role of cardiac magnetic resonance imaging in evaluating patients with eosinophilic granulomatosis with polyangiitis[J]. Cureus, 2020, 12(9): e10279.
[23] Liu S Y, Guo L, Zhang Z C, et al. Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors[J]. Ther Adv Chronic Dis, 2021, 12: 2040622320987051.
[24] Sinico R A, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome[J]. Am J Kidney Dis, 2006, 47(5): 770-779.
[25] Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients[J]. Arthritis Rheum, 2008, 58(2): 586-594.
[26] Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients[J]. Medicine: Baltimore, 1999, 78(1): 26-37.
[27] Liu S Y, Guo L, Fan X Y, et al. Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China[J]. Orphanet J Rare Dis, 2021, 16(1): 152.
[28] Zhang Z C, Liu S Y, Guo L, et al. Clinical characteristics of peripheral neuropathy in eosinophilic granulomatosis with polyangiitis: a retrospective single-center study in China[J]. J Immunol Res, 2020, 2020: 3530768.
[29] Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients[J]. Medicine: Baltimore, 1996, 75(1): 17-28.
[30] Li R L, Chen Y Y, Zhang S Z, et al. Clinical characteristics and long-term outcome of patients with gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis[J]. Front Immunol, 2022, 13: 1099722.
[31] Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients[J]. Arthritis Rheum, 2007, 57(4): 686-693.
|